Catalyst Oncology

WEDNESDAY, Oct. 22 (HealthDay News) — A new study suggests that people with advanced colon cancer who have a particular gene mutation won’t benefit from the medication cetuximab (Erbitux). While the drug can add months to the lives of people without a mutation in a gene called K-ras, those who have the mutation won’t see any benefit from this additional therapy, reports the study, which is published in the Oct. 23 issue of the New England Journal of Medicine. “We believe that, in the context

View post: 
Colon Cancer Drug Won’t Help Those With Certain Gene Mutation